[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Linet Americas\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":98},{"warningLetters":4,"total":97},[5,32,54,77],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},2206,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2023-02-14T14:20:00Z\">02\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-24T05:00:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cruise-lines-641736-01242023\">American Cruise Lines\u003C\u002Fa>"," Division of Human and Animal Food Operations East V ","Insanitary Conditions\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Paul E. Taiclet\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Vice President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>American Cruise Lines\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>741 Boston Post Road, Suite 200\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guilford\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06437\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Taiclet@americancruiselines.com\"> Taiclet@americancruiselines.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 24, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter 641736\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Taiclet:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your American Star and American Heritage vessels from April 30, 2022, through June 17, 2022, and from June 15, 2022, through August 15, 2022, respectively. FDA also conducted an investigation of the American Star and American Heritage vessels in December 2021. The investigation and inspections were initiated by FDA after three of your passengers who traveled in April 2021, September 2021, and September-October 2021 aboard these vessels were diagnosed with Legionnaires’ disease. American Cruise Lines and FDA were notified by the Centers for Disease Control and Prevention (CDC) of the first confirmed case of Legionnaires’ disease at the end of April 2021 (American Heritage), the second at the beginning of November 2021 (American Star), and the third at the end of November 2021 (American Heritage).\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>During our inspections, FDA investigators collected biofilm swabs and potable water samples from your American Star and American Heritage vessels. Laboratory Analysis of those samples identified \u003Cem>Legionella pneumophilia\u003C\u002Fem> serogroup 1 and \u003Cem>Legionella spp\u003C\u002Fem>. (hereinafter collectively called \u003Cem>Legionella\u003C\u002Fem>) in the potable water system of the vessels. FDA investigators also observed insanitary conditions related to the potable water systems onboard the vessels. At the conclusion of the inspections, the FDA investigators issued a Form FDA 483, Inspectional Observations, to both vessels.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the potable water onboard the American Star and American Heritage vessels is adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that it has been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth or rendered injurious to health.\u003C\u002Fp>\n\n\u003Cp>Additionally, the presence of \u003Cem>Legionella\u003C\u002Fem> in the potable water on the American Star and American Heritage vessels, as evidenced by the laboratory analysis of FDA’s water samples, causes your vessels’ potable water to be adulterated within the meaning of section 402(a)(1) of the Act [21 U.S.C. § 342(a)(1)] in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.\u003C\u002Fp>\n\n\u003Cp>We received your responses to the biofilm swabs and potable water positive results for \u003Cem>Legionella\u003C\u002Fem> and to the Form FDA 483 in regard to the American Star on the following dates: June 2, 2022, June 4, 2022, June 13, 2022, June 28, 2022, July 5, 2022, July 6, 2022, July 8, 2022, July 11, 2022, July 12, 2022, July 14, 2022, July 20, 2022, August 2, 2022, and August 16, 2022. We received your responses in regard to the American Heritage on July 19, 2022, August 1, 2022, August 16, 2022, and August 28, 2022.\u003C\u002Fp>\n\n\u003Cp>After reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continued concerns and to provide detailed information describing our findings.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Star\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Presence of \u003Cem>Legionella \u003C\u002Fem>Onboard the Vessel\u003C\u002Fp>\n\n\u003Cp>On April 30, 2022, FDA investigators collected ten (10) biofilm swabs and fourteen (14) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered \u003Cem>Legionella\u003C\u002Fem> from:\u003C\u002Fp>\n\n\u003Cp>Biofilm Swabs (60% of samples positive):\u003Cbr>\n• 5 Showerhead pipes in passenger cabins\u003Cbr>\n• Wait station hand sink faucet aerator in the galley\u003C\u002Fp>\n\n\u003Cp>Potable Water (93% of samples positive):\u003Cbr>\n• 7 Showerhead pipes in passenger cabins\u003Cbr>\n• 2 Showerhead pipes in crew rooms\u003Cbr>\n• Wait station hand sink faucet aerator in the galley\u003Cbr>\n• Galley prep sink faucet aerator\u003Cbr>\n• Potable water holding tank\u003Cbr>\n• Post pump \u003Cstrong>(b)(4)\u003C\u002Fstrong> hot water return spigot\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Post-Notification Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not change your procedures regarding potable water after CDC notified you on November 5, 2021, that one of your passengers was diagnosed with Legionnaires’ disease. For example, you did not change your procedures for flushing or disinfection and did not perform environmental sampling. Subsequently, after FDA notified you of its detection of \u003Cem>Legionella\u003C\u002Fem> onboard your vessel (June 2, 2022), you disinfected the vessel’s potable water system on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On June 4, 2022, you provided a letter to each passenger notifying them of the presence of \u003Cem>Legionella\u003C\u002Fem> in the potable water system onboard your vessel and mitigation steps you had taken. Also, you provided a letter notifying passengers who were onboard the vessel previously from May 3, 2022 to June 4, 2022.\u003C\u002Fp>\n\n\u003Cp>During the week of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you conducted water sampling using a field test kit. On June 24, 2022, FDA expressed concerns to you regarding the use of this field test kit and ending passenger notifications based on this testing because your testing was limited to \u003Cem>Legionella pneumophilia\u003C\u002Fem> serogroup 1 and did not include species identified as present on the vessel by FDA’s testing. In addition, FDA expressed concerns with the sensitivity, detection limit, and size of the water samples collected for the field test kit you used. On June 28, 2022, you shared additional sample collection results with FDA, separate from the field test kit, that were analyzed in a laboratory.\u003C\u002Fp>\n\n\u003Cp>FDA expressed concerns with these laboratory results not being representative nor sufficient to determine whether \u003Cem>Legionella\u003C\u002Fem> is still present and your use of these and the field test kit results to justify ending notification of passengers. Specifically, FDA collected 14 bulk water and 10 biofilm swab samples; you collected \u003Cstrong>(b)(4)\u003C\u002Fstrong> bulk water and \u003Cstrong>(b)(4)\u003C\u002Fstrong> biofilm swab samples for the laboratory tests. Thirteen of fourteen (92.86%) of FDA’s bulk water samples and 6 of 10 (60%) of FDA’s biofilm swab samples were positive for \u003Cem>Legionella\u003C\u002Fem>. You did not evaluate most of the bulk water and biofilm swab locations that were positive from FDA’s sampling. In addition, one of the biofilm swabs you took was from a \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was negative from FDA’s sampling.\u003C\u002Fp>\n\n\u003Cp>You restarted passenger notifications and provided them from July 9, 2022 to July 30, 2022. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you collected additional samples and notified FDA of negative results on August 16, 2022. On September 20, 2022, FDA submitted additional follow-up questions regarding the vessel’s sampling process, laboratory results, and future disinfection process. To date, we have not received a response.\u003C\u002Fp>\n\n\u003Cp>Further, in FDA’s emails to American Cruise Lines on July 11, 2022 and August 5, 2022, we reminded you that a voluntary corrective action plan to FDA would include not only testing for \u003Cem>Legionella\u003C\u002Fem>, but other documents, such as detailed procedures put in place onboard the vessel to address Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Vessel Inspection\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the following insanitary conditions and practices were observed: \u003Cem>Failure to Monitor Potable Water Parameters\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You did not monitor potable water parameters, such as free or total chlorine residual, temperature, and pH on the vessel when docked and not in operation or while in operation. Sample collection of biofilm swabs and potable water samples by FDA investigators on April 30, 2022, documented the following:\u003C\u002Fp>\n\n\u003Cp>Free chlorine and total chlorine residual were measured at 1.5ppm and 2ppm, respectively, in the potable water holding tanks where water is initially stored in the vessel. After the potable water traveled from the potable water holding tanks where initially stored to distal piping onboard the vessel such as showerheads, seven of 10 biofilm swabs and 10 of 14 bulk potable water samples had no free or total chlorine residual. The dissipation in chlorine residual from the potable water holding tanks to distal piping indicates that conditions, such as the presence of biofilm or planktonic microorganisms, led to the immediate use of the residual chlorine in the potable water system on the vessel.\u003C\u002Fp>\n\n\u003Cp>Eight of 10 biofilm swabs from showerhead pipes and a wait station hand sink faucet aerator and 11 of 14 bulk potable water samples had temperature ranges from 83.1°F - 112.6°F, which is ideal for \u003Cem>Legionella\u003C\u002Fem> growth.\u003C\u002Fp>\n\n\u003Cp>pH was measured between 5-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored.&nbsp;Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases &gt;7, with significant loss of efficacy at pH &gt;8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\u003C\u002Fp>\n\n\u003Cp>By monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage \u003Cem>Legionella\u003C\u002Fem> and other waterborne pathogens to grow. If you find that one or more of these parameters is not being met, the next step would be to take corrective actions to get conditions back within an acceptable range for the vessel’s potable water system.\u003C\u002Fp>\n\n\u003Cp>While the vessel \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the potable water system was flushed and filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Stagnant or standing water in a potable water system can increase the risk for growth and spread of \u003Cem>Legionella\u003C\u002Fem> and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the \u003Cem>Legionella\u003C\u002Fem> growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is also essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> (and other waterborne pathogens) to grow.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Monitor Disinfection Effectiveness\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>According to the Port Engineer, cabin outlets were allowed to run for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection when the vessel \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\u003C\u002Fp>\n\n\u003Cp>During the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system. Without verifying the disinfectant level, pH, and temperature during disinfection in a complex potable water system such as a vessel you cannot know whether the disinfection was effective in various areas of the potable water system. In addition, you did not perform environmental sampling of the potable water system, i.e., testing biofilm swabs and bulk potable water for microorganisms such as \u003Cem>Legionella\u003C\u002Fem>, to validate the effectiveness of the disinfection and your frequency of disinfection (\u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Cruise Lines’ Response\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We received your new Water Log on July 12, 2022, which provides for recording water samples from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for temperature, free chlorine, and pH. You changed the Water Log on August 17, 2022, to specify hot or cold water for each location. In addition, you created an additional Water Log, received by FDA on August 17, 2022, to record water samples for temperature, free chlorine, and pH \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the vessel.\u003C\u002Fp>\n\n\u003Cp>You have not provided detailed documentation of your new procedures related to water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. In addition, we have the following concerns regarding your Water Logs:\u003C\u002Fp>\n\n\u003Cp>Neither Water Log indicates your acceptable ranges for temperature and pH.\u003C\u002Fp>\n\n\u003Cp>Both Water Logs specify that free chlorine must be maintained at \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm. It is unclear how you established this level and whether it is the target level in cold only or both hot and cold water. Free chlorine that drops below an appropriately determined target level at a specific location could be indicative that additional corrective actions need to be considered, such as disinfection of the potable water system. Neither Water Log has a section for any corrective action(s) that may have occurred when free chlorine was detected below \u003Cstrong>(b)(4)\u003C\u002Fstrong> ppm. Therefore, it is not clear what you plan to do if this occurs.\u003C\u002Fp>\n\n\u003Cp>Both Water Logs specify \u003Cstrong>(b)(4)\u003C\u002Fstrong> for water collection; a vessel can be an extremely complex water system, and it is essential to consider \u003Cstrong>(b)(4)\u003C\u002Fstrong> for potable water parameters occurs. Also, water collection should focus on the hot water system because \u003Cem>Legionella\u003C\u002Fem> grows best in warm water; nearly all of FDA’s samples were taken from your hot water system.\u003C\u002Fp>\n\n\u003Cp>Also, timing is also essential to consider when monitoring potable water; potable water parameters taken after water has been stored on the vessel for a few days before refilling and\u002For flushing will provide different information compared to potable water parameters taken immediately after refilling and\u002For flushing. For example, a potable water holding tank that has just been flushed, refilled, and immediately sampled for potable water parameters would likely indicate the current parameters of the potable water taken onboard. A potable water tank that has not been flushed and\u002For refilled for a period of time such as a few days would be informative as to what occurs to the potable water after filling onboard and whether acceptable ranges of potable water parameters continue to be met. Your Water Logs do not specify when potable water parameters are to be taken.\u003C\u002Fp>\n\n\u003Cp>We note that both Water Logs refer only to free chlorine and not total chlorine. Vessels collect water from various locations; it is essential for the vessel to know what disinfectant such as chloramine or chlorine is being used by the potable water source being onloaded to the vessel. For example, if you take on water that is disinfected with chloramine, you would need to monitor both free chlorine and total chlorine.\u003C\u002Fp>\n\n\u003Cp>You have not provided additional information regarding how you will address the risk from stagnant water during docking. Further, it is not clear whether your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Logs are for use only during vessel operation or will also be used during docking. As explained previously, it is essential to monitor parameters such as free or total chlorine, temperatures, and pH when water is stagnant to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> to grow.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Heritage\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Presence of Legionella Onboard the Vessel\u003C\u002Fem>\u003Cbr>\nOn June 15, 2022, FDA investigators collected twenty-four (24) biofilm swabs and twenty-nine (29) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered \u003Cem>Legionella\u003C\u002Fem> from:\u003Cbr>\nBiofilm Swabs (8% of samples positive):\u003Cbr>\n• 1 Showerhead pipe in a passenger cabin\u003Cbr>\n• 1 Bathroom faucet aerator in a passenger cabin\u003C\u002Fp>\n\n\u003Cp>Potable Water (7% of samples positive)\u003Cbr>\n• 1 Showerhead pipe in a passenger cabin\u003Cbr>\n• 1 Bathroom faucet aerator in a passenger cabin\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Post-Notification Actions\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On April 30, 2021 and November 30, 2021 , you were notified by CDC of confirmed cases of Legionnaires’ disease. After being notified of two confirmed cases of Legionnaires’ disease with travel onboard the American Heritage, you did not change your procedures for flushing or disinfection and did not perform potable water or environmental sampling. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you disinfected the vessel’s potable water system. Subsequently, on June 15, 2022, FDA collected water and biofilm samples from the vessel. On July 14, 2022, FDA notified you of the positive findings regarding \u003Cem>Legionella\u003C\u002Fem> onboard the vessel. Subsequently, you provided notifications to each passenger on the voyage departing July 16, 2022, of the presence of \u003Cem>Legionella\u003C\u002Fem> in the potable water system. You also provided notifications to passengers onboard the vessel previously that departed on June 18, 2022, June 25, 2022, July 2, 2022, and July 9, 2022.\u003C\u002Fp>\n\n\u003Cp>FDA’s positive samples were collected after your \u003Cstrong>(b)(4)\u003C\u002Fstrong> disinfection and thus show that your disinfection was not fully effective. The passenger cabin where FDA detected \u003Cem>Legionella\u003C\u002Fem> in the showerhead pipe and bathroom faucet aerator is very distal to the potable water holding tanks and water heaters; distal locations are where routine chlorine levels would be lowest and hyperchlorination would be least effective. You subsequently disinfected the showerhead pipe and sink faucet aerator in the positive passenger cabin and installed a \u003Cstrong>(b)(4)\u003C\u002Fstrong> on the showerhead in that cabin to decrease the risk of exposure to \u003Cem>Legionella\u003C\u002Fem>. However, you have not performed any additional disinfection of the potable water system since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is prior to FDA’s collection of positive samples.\u003C\u002Fp>\n\n\u003Cp>We continue to have concerns with the potential exposure of passengers and crew members to \u003Cem>Legionella\u003C\u002Fem> onboard the American Heritage. We note that you have chosen not to do remediation and disinfect the potable water system after notification that the showerhead pipe and sink faucet aerator in a passenger cabin had biofilm swabs and potable water samples that tested positive for Legionella. FDA’s sampling results demonstrate that the disinfection performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, prior to the initial representative sampling by FDA, was not sufficient to address \u003Cem>Legionella\u003C\u002Fem> onboard the American Heritage. The device on the showerhead in the passenger cabin that assists in limiting exposure from showering does not address the overall concern that \u003Cem>Legionella\u003C\u002Fem> may be present in the vessel’s potable water system. Also, although you indicated that you disinfected the sink faucet aerator, you have not addressed the \u003Cem>Legionella\u003C\u002Fem> found in the biofilms from the pipe and in the sink faucet aerator of the passenger cabin. When \u003Cem>Legionella\u003C\u002Fem> is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine. You need to ensure that the disinfection procedures you use are effective for the removal of biofilms associated with \u003Cem>Legionella\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>As we have informed you previously, a voluntary corrective action plan would include documentation of detailed procedures put in place onboard the vessel for control of Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective. On July 21, 2022, FDA expressed concern that you had not provided a detailed disinfection process to be used in the future for the potable water system. On August 28, 2022, you provided a response which stated that you will do a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the vessel with no less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To date, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of \u003Cem>Legionella\u003C\u002Fem> when water is stagnant.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Vessel Inspection\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the following insanitary conditions and practices were observed:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Monitor Potable Water Parameters\u003C\u002Fem>\u003Cbr>\nYou did not monitor parameters of the potable water, such as free or total chlorine residual, temperatures, and pH on the vessel when docked and not in operation or while in operation.\u003C\u002Fp>\n\n\u003Cp>Sample collection of biofilm swabs and potable water samples by FDA investigators on June 15, 2022, documented the following:\u003C\u002Fp>\n\n\u003Cp>Nineteen of 24 biofilm swabs and 24 of 29 bulk potable water samples had no free or total chlorine residual. Lack of free and\u002For total chlorine indicates that conditions, such as the presence of biofilm or planktonic microorganisms may have led to the immediate use of this residual chlorine in the potable water system onboard the vessel.\u003C\u002Fp>\n\n\u003Cp>Twenty-two of 24 biofilm swabs and 26 of 29 bulk potable water samples had temperature ranges from 81.3°F - 113°F, which is ideal for potential \u003Cem>Legionella\u003C\u002Fem> growth.\u003C\u002Fp>\n\n\u003Cp>pH was measured between 6-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored. Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases &gt;7, with significant loss of efficacy at pH &gt;8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\u003C\u002Fp>\n\n\u003Cp>By monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage \u003Cem>Legionella\u003C\u002Fem> and other waterborne pathogens to grow. If you find that one or more of these parameters (e.g., pH, free or total chlorine, temperature) is not being met, the next step would be to take corrective actions to get conditions back to within an acceptable range for the vessel’s potable water system.\u003C\u002Fp>\n\n\u003Cp>While the vessel was \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the potable water system was flushed and filled \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Stagnant or standing water in a potable water system can increase the risk for growth and spread of \u003Cem>Legionella\u003C\u002Fem> and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the \u003Cem>Legionella\u003C\u002Fem> growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> (and other waterborne pathogens) to grow.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Failure to Monitor Disinfection Effectiveness\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>The Engineering Manager stated that disinfection was performed once from March 2021 to March 2022 and \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During disinfection, cabin outlets were allowed to run for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>. No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\u003C\u002Fp>\n\n\u003Cp>The disinfection consisted of forcing the potable water tanks to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and then flushing \u003Cstrong>(b)(4)\u003C\u002Fstrong> shower heads and sinks on the vessel. Afterwards, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was adjusted down to \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm to make the water potable again. During the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system.\u003C\u002Fp>\n\n\u003Cp>Further, the disinfection you performed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was not sufficient as demonstrated by FDA’s sampling results from June 15, 2022 that showed the presence of \u003Cem>Legionella\u003C\u002Fem> in a passenger cabin. Lack of verification of the disinfectant, pH, and temperature during disinfection in a complex potable water system such as a vessel prevents you from knowing whether the disinfection was effective in various areas of the potable water system. In addition, you did not sample the potable water system for microorganisms such as \u003Cem>Legionella\u003C\u002Fem> to verify the effectiveness of the disinfection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>American Cruise Lines’ Response\u003C\u002Fstrong>\u003Cbr>\nOn July 19, 2022, we received your new \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log, which provides for recording water samples for temperature, free chlorine, and pH. You stated that the updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log would reflect water samples from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the updated \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log would reflect water samples from the 22 same locations for the next 30 days inclusive of the showerhead pipes and sink faucet aerators that were positive for Legionella. On August 1, 2022, FDA received a new \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log and a \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log to replace the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Log and to be completed \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Aside from the Water Logs, we have not received documentation regarding your procedures for water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. We have similar concerns with regards to these Water Logs as we express earlier in this letter for the Water Logs for the American Star.\u003C\u002Fp>\n\n\u003Cp>Regarding disinfection during \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your August 28 response stated that you will do a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” of the vessel with no less than \u003Cstrong>(b)(4)\u003C\u002Fstrong>ppm of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a minimum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> when the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of Legionella when water is stagnant. Also, it is not clear whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water Logs you provided are for use only when the vessel is in operation or also will be used when the vessel is docked. As explained earlier, it is essential for you to monitor parameters such as pH, free or total chlorine residual, and temperatures during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and \u003Cem>Legionella\u003C\u002Fem> (and other waterborne pathogens) to grow. Water that stagnates for extended periods of time may allow for the growth of these biofilms, which can decrease the effectiveness of the disinfectant used. As a reminder, when \u003Cem>Legionella\u003C\u002Fem> is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine.\u003C\u002Fp>\n\n\u003Cp>Note that “Only potable water shall be provided for drinking and culinary purposes by any operator of a conveyance engaged in interstate traffic” (see 21 CFR 1240.80). Potable water is defined as “[w]ater which meets the standards prescribed in the Environmental Protection Agency's Primary Drinking Water Regulations as set forth in 40 CFR part 141 and the [FDA’s] sanitation requirements as set forth in [21 CFR Parts 1240 and 1250]” (see 21 CFR 1240.3).\u003C\u002Fp>\n\n\u003Cp>Finally, we note that you have other vessels in your fleet. Although we are not aware of a case of Legionnaires’ disease being associated with any of those vessels, based on your practices on the American Star and American Heritage, we have concerns about the potable water on your other vessels. Specifically, if adequate practices are not followed regarding potable water on those vessels, there is a potential for waterborne illnesses to occur. It would not be appropriate to wait until there is a confirmed case of Legionnaires’ disease to address the water practices onboard those other vessels. As a reminder, people at increased risk of Legionnaire’s disease include those 50 years of age or older and we understand that the majority of your passengers onboard the American Star and American Heritage exceed this age.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your vessels. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to Stephen Rabe, Compliance Officer, via email at: ORAHAFEAST5FirmResponses@fda.hhs.gov or to U.S. Food and Drug Administration, 550 Main Street, Suite 4-930, Cincinnati, OH 45202. If you have any questions about the content of this letter, you may contact Mr. Rabe at 513-322-0660.\u003C\u002Fp>\n\n\u003Cp>Please also send a copy of the reply to Beira Montalvo, Compliance Officer, via email at: Beira.Montalvo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDivision Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast 5\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Notification by CDC is based on travel on a cruise ship during any of the 14 days before symptom onset. Notification does not mean that the vessel is the source of infection.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPaul E. Taiclet\n\nRecipient Title\n\nExecutive Vice President\n\nAmerican Cruise Lines\n\n741 Boston Post Road, Suite 200\n\nGuilford, CT 06437\n\nUnited States\n\nTaiclet@americancruiselines.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nJanuary 24, 2023\n\nWarning Letter 641736\n\nDear Mr. Taiclet:\n\nThe United States Food and Drug Administration (FDA) inspected your American Star and American Heritage vessels from April 30, 2022, through June 17, 2022, and from June 15, 2022, through August 15, 2022, respectively. FDA also conducted an investigation of the American Star and American Heritage vessels in December 2021. The investigation and inspections were initiated by FDA after three of your passengers who traveled in April 2021, September 2021, and September-October 2021 aboard these vessels were diagnosed with Legionnaires’ disease. American Cruise Lines and FDA were notified by the Centers for Disease Control and Prevention (CDC) of the first confirmed case of Legionnaires’ disease at the end of April 2021 (American Heritage), the second at the beginning of November 2021 (American Star), and the third at the end of November 2021 (American Heritage).1\n\nDuring our inspections, FDA investigators collected biofilm swabs and potable water samples from your American Star and American Heritage vessels. Laboratory Analysis of those samples identified Legionella pneumophilia serogroup 1 and Legionella spp. (hereinafter collectively called Legionella) in the potable water system of the vessels. FDA investigators also observed insanitary conditions related to the potable water systems onboard the vessels. At the conclusion of the inspections, the FDA investigators issued a Form FDA 483, Inspectional Observations, to both vessels.\n\nBased on FDA’s inspectional findings, we have determined that the potable water onboard the American Star and American Heritage vessels is adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that it has been prepared, packed or held under insanitary conditions whereby it may have been contaminated with filth or rendered injurious to health.\n\nAdditionally, the presence of Legionella in the potable water on the American Star and American Heritage vessels, as evidenced by the laboratory analysis of FDA’s water samples, causes your vessels’ potable water to be adulterated within the meaning of section 402(a)(1) of the Act [21 U.S.C. § 342(a)(1)] in that it bears or contains a poisonous or deleterious substance which may render it injurious to health.\n\nWe received your responses to the biofilm swabs and potable water positive results for Legionella and to the Form FDA 483 in regard to the American Star on the following dates: June 2, 2022, June 4, 2022, June 13, 2022, June 28, 2022, July 5, 2022, July 6, 2022, July 8, 2022, July 11, 2022, July 12, 2022, July 14, 2022, July 20, 2022, August 2, 2022, and August 16, 2022. We received your responses in regard to the American Heritage on July 19, 2022, August 1, 2022, August 16, 2022, and August 28, 2022.\n\nAfter reviewing the inspectional findings and your responses, we are issuing this letter to advise you of FDA’s continued concerns and to provide detailed information describing our findings.\n\nAmerican Star\n\nPresence of Legionella Onboard the Vessel\n\nOn April 30, 2022, FDA investigators collected ten (10) biofilm swabs and fourteen (14) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered Legionella from:\n\nBiofilm Swabs (60% of samples positive):\n\n• 5 Showerhead pipes in passenger cabins\n\n• Wait station hand sink faucet aerator in the galley\n\nPotable Water (93% of samples positive):\n\n• 7 Showerhead pipes in passenger cabins\n\n• 2 Showerhead pipes in crew rooms\n\n• Wait station hand sink faucet aerator in the galley\n\n• Galley prep sink faucet aerator\n\n• Potable water holding tank\n\n• Post pump (b)(4) hot water return spigot\n\nPost-Notification Actions\n\nYou did not change your procedures regarding potable water after CDC notified you on November 5, 2021, that one of your passengers was diagnosed with Legionnaires’ disease. For example, you did not change your procedures for flushing or disinfection and did not perform environmental sampling. Subsequently, after FDA notified you of its detection of Legionella onboard your vessel (June 2, 2022), you disinfected the vessel’s potable water system on (b)(4). On June 4, 2022, you provided a letter to each passenger notifying them of the presence of Legionella in the potable water system onboard your vessel and mitigation steps you had taken. Also, you provided a letter notifying passengers who were onboard the vessel previously from May 3, 2022 to June 4, 2022.\n\nDuring the week of (b)(4), you conducted water sampling using a field test kit. On June 24, 2022, FDA expressed concerns to you regarding the use of this field test kit and ending passenger notifications based on this testing because your testing was limited to Legionella pneumophilia serogroup 1 and did not include species identified as present on the vessel by FDA’s testing. In addition, FDA expressed concerns with the sensitivity, detection limit, and size of the water samples collected for the field test kit you used. On June 28, 2022, you shared additional sample collection results with FDA, separate from the field test kit, that were analyzed in a laboratory.\n\nFDA expressed concerns with these laboratory results not being representative nor sufficient to determine whether Legionella is still present and your use of these and the field test kit results to justify ending notification of passengers. Specifically, FDA collected 14 bulk water and 10 biofilm swab samples; you collected (b)(4) bulk water and (b)(4) biofilm swab samples for the laboratory tests. Thirteen of fourteen (92.86%) of FDA’s bulk water samples and 6 of 10 (60%) of FDA’s biofilm swab samples were positive for Legionella. You did not evaluate most of the bulk water and biofilm swab locations that were positive from FDA’s sampling. In addition, one of the biofilm swabs you took was from a (b)(4) that was negative from FDA’s sampling.\n\nYou restarted passenger notifications and provided them from July 9, 2022 to July 30, 2022. On (b)(4), you collected additional samples and notified FDA of negative results on August 16, 2022. On September 20, 2022, FDA submitted additional follow-up questions regarding the vessel’s sampling process, laboratory results, and future disinfection process. To date, we have not received a response.\n\nFurther, in FDA’s emails to American Cruise Lines on July 11, 2022 and August 5, 2022, we reminded you that a voluntary corrective action plan to FDA would include not only testing for Legionella, but other documents, such as detailed procedures put in place onboard the vessel to address Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective.\n\nVessel Inspection\n\nDuring the inspection, the following insanitary conditions and practices were observed: Failure to Monitor Potable Water Parameters\n\nYou did not monitor potable water parameters, such as free or total chlorine residual, temperature, and pH on the vessel when docked and not in operation or while in operation. Sample collection of biofilm swabs and potable water samples by FDA investigators on April 30, 2022, documented the following:\n\nFree chlorine and total chlorine residual were measured at 1.5ppm and 2ppm, respectively, in the potable water holding tanks where water is initially stored in the vessel. After the potable water traveled from the potable water holding tanks where initially stored to distal piping onboard the vessel such as showerheads, seven of 10 biofilm swabs and 10 of 14 bulk potable water samples had no free or total chlorine residual. The dissipation in chlorine residual from the potable water holding tanks to distal piping indicates that conditions, such as the presence of biofilm or planktonic microorganisms, led to the immediate use of the residual chlorine in the potable water system on the vessel.\n\nEight of 10 biofilm swabs from showerhead pipes and a wait station hand sink faucet aerator and 11 of 14 bulk potable water samples had temperature ranges from 83.1°F - 112.6°F, which is ideal for Legionella growth.\n\npH was measured between 5-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored. Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases >7, with significant loss of efficacy at pH >8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\n\nBy monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage Legionella and other waterborne pathogens to grow. If you find that one or more of these parameters is not being met, the next step would be to take corrective actions to get conditions back within an acceptable range for the vessel’s potable water system.\n\nWhile the vessel (b)(4), the potable water system was flushed and filled (b)(4). Stagnant or standing water in a potable water system can increase the risk for growth and spread of Legionella and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the Legionella growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is also essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella (and other waterborne pathogens) to grow.\n\nFailure to Monitor Disinfection Effectiveness\n\nAccording to the Port Engineer, cabin outlets were allowed to run for approximately (b)(4) during (b)(4) disinfection when the vessel (b)(4). No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\n\nDuring the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system. Without verifying the disinfectant level, pH, and temperature during disinfection in a complex potable water system such as a vessel you cannot know whether the disinfection was effective in various areas of the potable water system. In addition, you did not perform environmental sampling of the potable water system, i.e., testing biofilm swabs and bulk potable water for microorganisms such as Legionella, to validate the effectiveness of the disinfection and your frequency of disinfection ((b)(4)).\n\nAmerican Cruise Lines’ Response\n\nWe received your new Water Log on July 12, 2022, which provides for recording water samples from (b)(4) for temperature, free chlorine, and pH. You changed the Water Log on August 17, 2022, to specify hot or cold water for each location. In addition, you created an additional Water Log, received by FDA on August 17, 2022, to record water samples for temperature, free chlorine, and pH (b)(4) on (b)(4) from (b)(4) on the vessel.\n\nYou have not provided detailed documentation of your new procedures related to water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. In addition, we have the following concerns regarding your Water Logs:\n\nNeither Water Log indicates your acceptable ranges for temperature and pH.\n\nBoth Water Logs specify that free chlorine must be maintained at (b)(4)ppm. It is unclear how you established this level and whether it is the target level in cold only or both hot and cold water. Free chlorine that drops below an appropriately determined target level at a specific location could be indicative that additional corrective actions need to be considered, such as disinfection of the potable water system. Neither Water Log has a section for any corrective action(s) that may have occurred when free chlorine was detected below (b)(4) ppm. Therefore, it is not clear what you plan to do if this occurs.\n\nBoth Water Logs specify (b)(4) for water collection; a vessel can be an extremely complex water system, and it is essential to consider (b)(4) for potable water parameters occurs. Also, water collection should focus on the hot water system because Legionella grows best in warm water; nearly all of FDA’s samples were taken from your hot water system.\n\nAlso, timing is also essential to consider when monitoring potable water; potable water parameters taken after water has been stored on the vessel for a few days before refilling and\u002For flushing will provide different information compared to potable water parameters taken immediately after refilling and\u002For flushing. For example, a potable water holding tank that has just been flushed, refilled, and immediately sampled for potable water parameters would likely indicate the current parameters of the potable water taken onboard. A potable water tank that has not been flushed and\u002For refilled for a period of time such as a few days would be informative as to what occurs to the potable water after filling onboard and whether acceptable ranges of potable water parameters continue to be met. Your Water Logs do not specify when potable water parameters are to be taken.\n\nWe note that both Water Logs refer only to free chlorine and not total chlorine. Vessels collect water from various locations; it is essential for the vessel to know what disinfectant such as chloramine or chlorine is being used by the potable water source being onloaded to the vessel. For example, if you take on water that is disinfected with chloramine, you would need to monitor both free chlorine and total chlorine.\n\nYou have not provided additional information regarding how you will address the risk from stagnant water during docking. Further, it is not clear whether your (b)(4) and (b)(4) Water Logs are for use only during vessel operation or will also be used during docking. As explained previously, it is essential to monitor parameters such as free or total chlorine, temperatures, and pH when water is stagnant to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella to grow.\n\nAmerican Heritage\n\nPresence of Legionella Onboard the Vessel\n\nOn June 15, 2022, FDA investigators collected twenty-four (24) biofilm swabs and twenty-nine (29) bulk one-liter potable water samples from various locations on your vessel. The Maryland Department of Health laboratory recovered Legionella from:\n\nBiofilm Swabs (8% of samples positive):\n\n• 1 Showerhead pipe in a passenger cabin\n\n• 1 Bathroom faucet aerator in a passenger cabin\n\nPotable Water (7% of samples positive)\n\n• 1 Showerhead pipe in a passenger cabin\n\n• 1 Bathroom faucet aerator in a passenger cabin\n\nPost-Notification Actions\n\nOn April 30, 2021 and November 30, 2021 , you were notified by CDC of confirmed cases of Legionnaires’ disease. After being notified of two confirmed cases of Legionnaires’ disease with travel onboard the American Heritage, you did not change your procedures for flushing or disinfection and did not perform potable water or environmental sampling. On (b)(4), you disinfected the vessel’s potable water system. Subsequently, on June 15, 2022, FDA collected water and biofilm samples from the vessel. On July 14, 2022, FDA notified you of the positive findings regarding Legionella onboard the vessel. Subsequently, you provided notifications to each passenger on the voyage departing July 16, 2022, of the presence of Legionella in the potable water system. You also provided notifications to passengers onboard the vessel previously that departed on June 18, 2022, June 25, 2022, July 2, 2022, and July 9, 2022.\n\nFDA’s positive samples were collected after your (b)(4) disinfection and thus show that your disinfection was not fully effective. The passenger cabin where FDA detected Legionella in the showerhead pipe and bathroom faucet aerator is very distal to the potable water holding tanks and water heaters; distal locations are where routine chlorine levels would be lowest and hyperchlorination would be least effective. You subsequently disinfected the showerhead pipe and sink faucet aerator in the positive passenger cabin and installed a (b)(4) on the showerhead in that cabin to decrease the risk of exposure to Legionella. However, you have not performed any additional disinfection of the potable water system since (b)(4), which is prior to FDA’s collection of positive samples.\n\nWe continue to have concerns with the potential exposure of passengers and crew members to Legionella onboard the American Heritage. We note that you have chosen not to do remediation and disinfect the potable water system after notification that the showerhead pipe and sink faucet aerator in a passenger cabin had biofilm swabs and potable water samples that tested positive for Legionella. FDA’s sampling results demonstrate that the disinfection performed on (b)(4), prior to the initial representative sampling by FDA, was not sufficient to address Legionella onboard the American Heritage. The device on the showerhead in the passenger cabin that assists in limiting exposure from showering does not address the overall concern that Legionella may be present in the vessel’s potable water system. Also, although you indicated that you disinfected the sink faucet aerator, you have not addressed the Legionella found in the biofilms from the pipe and in the sink faucet aerator of the passenger cabin. When Legionella is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine. You need to ensure that the disinfection procedures you use are effective for the removal of biofilms associated with Legionella.\n\nAs we have informed you previously, a voluntary corrective action plan would include documentation of detailed procedures put in place onboard the vessel for control of Legionella, documentation of those procedures being accomplished, and verification that those procedures are effective. On July 21, 2022, FDA expressed concern that you had not provided a detailed disinfection process to be used in the future for the potable water system. On August 28, 2022, you provided a response which stated that you will do a “(b)(4)” of the vessel with no less than (b)(4)ppm of (b)(4) for a minimum of (b)(4) when (b)(4). To date, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of Legionella when water is stagnant.\n\nVessel Inspection\n\nDuring the inspection, the following insanitary conditions and practices were observed:\n\nFailure to Monitor Potable Water Parameters\n\nYou did not monitor parameters of the potable water, such as free or total chlorine residual, temperatures, and pH on the vessel when docked and not in operation or while in operation.\n\nSample collection of biofilm swabs and potable water samples by FDA investigators on June 15, 2022, documented the following:\n\nNineteen of 24 biofilm swabs and 24 of 29 bulk potable water samples had no free or total chlorine residual. Lack of free and\u002For total chlorine indicates that conditions, such as the presence of biofilm or planktonic microorganisms may have led to the immediate use of this residual chlorine in the potable water system onboard the vessel.\n\nTwenty-two of 24 biofilm swabs and 26 of 29 bulk potable water samples had temperature ranges from 81.3°F - 113°F, which is ideal for potential Legionella growth.\n\npH was measured between 6-7 for biofilm swabs and bulk potable water samples. pH level is important to consider as it impacts the effectiveness of the chlorine residual. pH can also cause potential corrosion of potable water pipes when not carefully monitored. Unlike temperature, it is not possible to set a single target value for pH since there are several factors that a water operator would use to determine the target. The efficacy of chlorination is affected by many factors, one of which is pH. The efficacy of chlorine declines as pH increases >7, with significant loss of efficacy at pH >8. While the optimum pH range for systems treated with monochloramine is 7.5 to 9.0, it is important to know how your source water is treated to determine the appropriate pH range for each of your systems.\n\nBy monitoring these parameters, you can ensure that the vessel’s potable water system is operating in a way to minimize hazardous conditions that could encourage Legionella and other waterborne pathogens to grow. If you find that one or more of these parameters (e.g., pH, free or total chlorine, temperature) is not being met, the next step would be to take corrective actions to get conditions back to within an acceptable range for the vessel’s potable water system.\n\nWhile the vessel was (b)(4), the potable water system was flushed and filled (b)(4). Stagnant or standing water in a potable water system can increase the risk for growth and spread of Legionella and other biofilm-associated bacteria. When water is stagnant, hot water temperatures can decrease to the Legionella growth range. Stagnant water can also lead to low or undetectable levels of disinfectant, such as chlorine. Therefore, it is essential for you to monitor parameters such as free or total chlorine residual, temperatures, and pH during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella (and other waterborne pathogens) to grow.\n\nFailure to Monitor Disinfection Effectiveness\n\nThe Engineering Manager stated that disinfection was performed once from March 2021 to March 2022 and (b)(4) during (b)(4) from (b)(4). During disinfection, cabin outlets were allowed to run for approximately (b)(4). No specific sequence was given to crew in the galley, crew quarters, and various other cabins for turning on the faucets, taps, showerheads, and other locations to run the disinfectant.\n\nThe disinfection consisted of forcing the potable water tanks to a (b)(4) concentration of (b)(4)ppm for (b)(4) and then flushing (b)(4) shower heads and sinks on the vessel. Afterwards, the (b)(4) was adjusted down to (b)(4)ppm to make the water potable again. During the disinfection, you did not measure the disinfectant level, pH, and temperature to verify that an adequate amount of the disinfectant at an appropriate pH and temperature reached the proximal, medial, and distal faucets and showerheads and other areas that are part of the potable water system.\n\nFurther, the disinfection you performed on (b)(4), was not sufficient as demonstrated by FDA’s sampling results from June 15, 2022 that showed the presence of Legionella in a passenger cabin. Lack of verification of the disinfectant, pH, and temperature during disinfection in a complex potable water system such as a vessel prevents you from knowing whether the disinfection was effective in various areas of the potable water system. In addition, you did not sample the potable water system for microorganisms such as Legionella to verify the effectiveness of the disinfection.\n\nAmerican Cruise Lines’ Response\n\nOn July 19, 2022, we received your new (b)(4) and (b)(4) Water Log, which provides for recording water samples for temperature, free chlorine, and pH. You stated that the updated (b)(4) Water Log would reflect water samples from (b)(4), and the updated (b)(4) Water Log would reflect water samples from the 22 same locations for the next 30 days inclusive of the showerhead pipes and sink faucet aerators that were positive for Legionella. On August 1, 2022, FDA received a new (b)(4) Water Log and a (b)(4) Water Log to replace the (b)(4) Water Log and to be completed (b)(4) from (b)(4).\n\nAside from the Water Logs, we have not received documentation regarding your procedures for water monitoring, documentation of these procedures being accomplished (i.e., completed Water Logs), and verification that these procedures are effective. We have similar concerns with regards to these Water Logs as we express earlier in this letter for the Water Logs for the American Star.\n\nRegarding disinfection during (b)(4), your August 28 response stated that you will do a “(b)(4)” of the vessel with no less than (b)(4)ppm of (b)(4) for a minimum of (b)(4) when the (b)(4). However, you have not provided any procedures for how you will accomplish this and to show that it is adequate to address the increased risk of Legionella when water is stagnant. Also, it is not clear whether the (b)(4) and (b)(4) Water Logs you provided are for use only when the vessel is in operation or also will be used when the vessel is docked. As explained earlier, it is essential for you to monitor parameters such as pH, free or total chlorine residual, and temperatures during water stagnation to determine whether your frequency of flushing and filling is adequate to minimize hazardous conditions that could encourage biofilm development and Legionella (and other waterborne pathogens) to grow. Water that stagnates for extended periods of time may allow for the growth of these biofilms, which can decrease the effectiveness of the disinfectant used. As a reminder, when Legionella is associated with a protozoa, including amoebae (as can be the case with a biofilm present), it can be more resistant to disinfection such as the use of chlorine.\n\nNote that “Only potable water shall be provided for drinking and culinary purposes by any operator of a conveyance engaged in interstate traffic” (see 21 CFR 1240.80). Potable water is defined as “[w]ater which meets the standards prescribed in the Environmental Protection Agency's Primary Drinking Water Regulations as set forth in 40 CFR part 141 and the [FDA’s] sanitation requirements as set forth in [21 CFR Parts 1240 and 1250]” (see 21 CFR 1240.3).\n\nFinally, we note that you have other vessels in your fleet. Although we are not aware of a case of Legionnaires’ disease being associated with any of those vessels, based on your practices on the American Star and American Heritage, we have concerns about the potable water on your other vessels. Specifically, if adequate practices are not followed regarding potable water on those vessels, there is a potential for waterborne illnesses to occur. It would not be appropriate to wait until there is a confirmed case of Legionnaires’ disease to address the water practices onboard those other vessels. As a reminder, people at increased risk of Legionnaire’s disease include those 50 years of age or older and we understand that the majority of your passengers onboard the American Star and American Heritage exceed this age.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your vessels. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to Stephen Rabe, Compliance Officer, via email at: ORAHAFEAST5FirmResponses@fda.hhs.gov or to U.S. Food and Drug Administration, 550 Main Street, Suite 4-930, Cincinnati, OH 45202. If you have any questions about the content of this letter, you may contact Mr. Rabe at 513-322-0660.\n\nPlease also send a copy of the reply to Beira Montalvo, Compliance Officer, via email at: Beira.Montalvo@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDivision Director\n\nOffice of Human and Animal Food Operations\n\nEast 5\n\n_________________________________\n\n1 Notification by CDC is based on travel on a cruise ship during any of the 14 days before symptom onset. Notification does not mean that the vessel is the source of infection.","American Cruise Lines","american-cruise-lines-641736-01242023","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famerican-cruise-lines-641736-01242023","2026-10-26T08:07:54.752621+00:00","Warning Letter","Issued","2023-02-14","641736","Food & Beverages","Division of Human and Animal Food Operations East V","Paul E. Taiclet","2026-08-20T01:15:11.36+00:00","United Parcel Service","2023-01-24",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":23,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":19,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":19,"reference_number":19,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},2923,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2022-01-18T14:20:00Z\">01\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-21T05:00:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsunstar-americas-inc-614058-12212021\">Sunstar Americas, Inc.\u003C\u002Fa>","Office of Medical Devices and Radiological Health Operations Div. 2 Central","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard McMahon\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sunstar Americas, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>301 E. Central Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Schaumburg\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60195\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health Operations Div. 2 Central\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter # 614058\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 21, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. McMahon:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Sunstar Americas, Inc., FEI 1413787, at 301 E. Central Rd., Schaumburg, Illinois, from January 12 to February 18, 2021.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the FD&amp;C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\u003C\u002Fp>\n\n\u003Cp>This inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&amp;C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\u003C\u002Fp>\n\n\u003Cp>We reviewed your March 11, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of its written production and process control procedures (21 CFR 211.100(a) and (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our investigators documented deficiencies in the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;system) validation protocol and deviations during its execution. For example:\u003C\u002Fp>\n\n\u003Cp>• Excursions in the performance parameters of your water system occurred while the system was being validated. For example, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> concentration, which impacts the ability of the system to maintain microbiological control, was recorded at \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the system storage tank. \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurements were below the limit of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> days in January 2018. These occurrences were not documented in the validation report as deviations and reviewed before you deemed the water system validated.\u003C\u002Fp>\n\n\u003Cp>• The water system validation study did not provide scientific data supporting the type and frequency of chemical sanitization performed in addition to the routine \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization. Your protocol also lacked provisions for evaluating these parameters of your water system sanitization program. Your current practice is to conduct chemical sanitization \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>• The protocol allowed for reduced sampling and testing if results were considered acceptable but you did not define what an acceptable standard would be. Although you had results as high as \u003Cstrong>(b)(4)\u003C\u002Fstrong> at your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you still reduced sampling and testing to a \u003Cstrong>(b)(4)\u003C\u002Fstrong> frequency.\u003C\u002Fp>\n\n\u003Cp>You have not shown that your water system can consistently produce water suitable for drug manufacturing and meets, at a minimum, the USP purified water monograph and appropriate microbial limits.\u003C\u002Fp>\n\n\u003Cp>It is essential that you design your water system to ensure consistently high purity water that is suitable for its intended use. High bioburden or objectionable microbes in the water used as an ingredient in your drugs may pose significant risk to consumers.\u003C\u002Fp>\n\n\u003Cp>In your response, you committed to reassessing your water system followed by revalidation. You also committed to conducting a gap assessment of your validation program and performing comprehensive CGMP and quality systems training for all personnel.\u003C\u002Fp>\n\n\u003Cp>In response to this letter provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent assessment of your water system design, control, and maintenance, and corresponding corrective actions and preventative actions (CAPA).\u003C\u002Fp>\n\n\u003Cp>• A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\u003C\u002Fp>\n\n\u003Cp>• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your water system was subject to microbiological contamination and numerous deviations from operating parameters since validation. Many of these deviations were either not investigated or did not result in implementation of CAPA.\u003C\u002Fp>\n\n\u003Cp>• No investigations were conducted in response to identification of \u003Cem>Burkholderia contaminans\u003C\u002Fem> in seven samples taken from your water system ports \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, between January 1, 2020, and June 30, 2020. \u003Cem>Burkholderia contaminans\u003C\u002Fem> was not identified as an objectionable organism in your procedures or your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water specifications. The presence of objectionable microorganisms in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system can adversely affect the quality of your drug products.\u003C\u002Fp>\n\n\u003Cp>• You opened a CAPA during the validation of your water system due to findings of \u003Cem>Burkholderia cepacia\u003C\u002Fem> in three samples collected at ports \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. These ports supply water for manufacturing. The CAPA investigation identified a possible root cause of a “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> supply port to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample port and your firm proposed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, the CAPA was closed approximately a year and a half later without addition of the filter or explanation why corrective action was not taken. You subsequently identified \u003Cem>Burkholderia contaminans\u003C\u002Fem> at port \u003Cstrong>(b)(4)\u003C\u002Fstrong> multiple times in 2020.\u003C\u002Fp>\n\n\u003Cp>• During the validation of your water system, a third-party service technician observed staining inside the water tank and noted you were investigating the cause. You lacked documentation of the cause or CAPA addressing the service technician’s finding.\u003C\u002Fp>\n\n\u003Cp>• Deviations in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization process were not logged in accordance with your deviation procedure. We found a pattern of failure to conduct investigations or implement CAPA following deviations in the operating parameters during ozone sanitization when the minimum level of \u003Cstrong>(b)(4)\u003C\u002Fstrong> was not met in the storage tank, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and loop supply.\u003C\u002Fp>\n\n\u003Cp>In your response, you committed to hire a third-party expert and to perform training on investigations. You also committed to performing a review of all CAPA, out-of-specification (OOS), out-of-trend (OOT), and invalidated quality control data initiated from January 1, 2019, to present. You also revised your purified water specifications to include Burkholderia cepacia complex (BCC) as an objectionable organism as of January 11, 2021.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you failed to accurately categorize some OOS and OOT results, deviations, and unexpected discrepancies.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A retrospective, independent review of all invalidated OOS (including in-process, release, and stability testing) results for US products irrespective of whether the batch was ultimately distributed in the US and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>\n&nbsp; o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>\n&nbsp; o For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>\n&nbsp; o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive retrospective review of all GMP documentation associated with distributed finished drug product batches that remain within expiry and the equipment and systems used in their manufacture to ensure all OOS results, OOT results, deviations, and unexpected discrepancies were categorized and appropriately investigated.\u003C\u002Fp>\n\n\u003Cp>• Explain whether you have reconsidered the sequence of the water system components in your current design. You currently have \u003Cstrong>(b)(4)\u003C\u002Fstrong> system although the latter represents the best means of microbial reduction.\u003C\u002Fp>\n\n\u003Cp>• A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fp>\n\n\u003Cp>• A detailed description of all CAPA that have been identified to address this violation, with timeframes for CAPA activities.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to&nbsp;assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Before beginning distribution, you did not adequately study antimicrobial effectiveness in your finished drugs products to evaluate the ability of the preservative system to inhibit the growth of certain objectionable organisms including BCC.\u003C\u002Fp>\n\n\u003Cp>For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> studies for 0.12% chlorhexidine gluconate oral rinse (Paroex) using \u003Cem>Burkholderia cepacia\u003C\u002Fem> were not performed until July 2020. Notably, BCC was found to proliferate to excessive levels in your product over its shelf life for several batches including too numerous to count (TNTC) levels. Numerous lots of this product were recalled from the market because of excessive microbiological contamination. Paroex is produced by a contract manufacturer under your ANDA 076434.\u003C\u002Fp>\n\n\u003Cp>In your response, you committed to assessing your procedure titled “U.S. Regulatory Information Concerning SAI Products” to determine its adequacy in establishing and maintaining product-specific information and meeting regulatory requirements.\u003C\u002Fp>\n\n\u003Cp>You committed to adding BCC to microbiological tests for products manufactured at and for your firm. You also committed to developing and implementing a procedure to establish steps to follow when a new microorganism is identified in the manufacturing facility to ensure the adequacy of controls, including addressing potentially objectionable microorganisms.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, describe how your product and process development programs will build quality into your products, including conducting appropriate studies to support each new product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately exercise your responsibility to ensure all drug products manufactured by and for your firm possessed appropriate quality attributes, antimicrobial properties, or preservative systems to ensure their microbiological quality and safety. For example, your non-sterile aqueous-based drug product specifications did not include \u003Cem>Burkholderia cepacia\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>Your drugs are often used in hospitals or clinical settings in which patients may have a higher vulnerability to infection with \u003Cem>Burkholderia cepacia\u003C\u002Fem> and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\u003C\u002Fp>\n\n\u003Cp>The agreement between your firm and your contract manufacturer (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) specifically identified your responsibilities with respect to the manufacture of your drug products. Your responsibilities include the provision of support regarding technical and regulatory issues to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the products’ manufacture. You are also responsible for overseeing the CGMP compliance of your contract manufacturer through mechanisms including the review of procedures and records associated with the manufacture of your products.\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that you initially recalled batches of Paroex bearing an expiration date from June 30, 2022, to September 30, 2022, because of the presence of objectionable microbiological contamination or substantial risk of contamination. We also acknowledge your expansion of the recall to include all potentially affected lots of Paroex following further discussions with FDA. We also acknowledge your subsequent recalls of Hydral Dry Mouth Relief, Butler Clear Dip, and Perioshield Oral Health Rinse, medical devices, because of potential contamination with objectionable organisms.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of your drugs regardless of whether you manufacture them, or a contract facility manufactures them for you on your behalf. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide your updated procedures that ensure all activities performed by you and your contract manufacturers are adequate and approved by your quality unit.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Medical Device Quality System Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Your firm failed to adequately validate a process whose results cannot be fully verified by subsequent inspection and test through established procedures (21 CFR 820.75(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer above to the discussion of 21 CFR 211.100(a) and (b) violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Your failed to adequately establish procedures for corrective and preventive action to include the documentation of such activities (21 CFR 820.100(a) &amp; (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Refer above to the discussion of 21 CFR 211.192 violations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>7. Failure to adequately establish schedules for the adjustment, cleaning, and other maintenance of equipment (21 CFR 820.70(g)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitization system of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system was not part of a maintenance schedule. The system included three gauges that measure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the system to verify that the sanitization process and the storage tank control are acceptable. There was no documentation that gauges (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) had been calibrated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>8. Failure to adequately establish procedures for design input (21 CFR 820.30(c)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Specifically, the design for Hydral Spray failed to include \u003Cem>Burkholderia cepacia\u003C\u002Fem> as a challenge in \u003Cstrong>(b)(4)\u003C\u002Fstrong> although \u003Cem>Burkholderia cepacia\u003C\u002Fem> was included in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> challenge for other products to include the \u003Cstrong>(b)(4)\u003C\u002Fstrong> toothpaste in June 2017. The risk management file of the Hydral Spray was not updated to include these objectionable organisms and any controls necessary to mitigate the risks as part of Hydral spray design verification and validation. The risk management file was updated on January 18, 2021, after the start of the FDA inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: \u003Cem>Q8(R2) Pharmaceutical Development\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload\u003C\u002Fa>, \u003Cem>Q9 Quality Risk Management\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71543\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71543\u002Fdownload\u003C\u002Fa> and \u003Cem>Q10 Pharmaceutical Quality System\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Objectionable Organisms\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For further information regarding the significance of \u003Cem>Burkholderia cepacia\u003C\u002Fem> complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\">https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to suspend production of drugs at this facility.\u003C\u002Fp>\n\n\u003Cp>If you plan to resume manufacturing drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility and in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (614058). Please address your reply via email to: oradevices2firmresponse@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Rafael Padilla. Compliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Rafael Padilla at (312) 596-4212.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Blake Bevill, M.S.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Jeffrey Meng\u003Cbr>\nActing Program Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations Division III\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Richard McMahon\n\nRecipient Title\n\nManaging Director\n\nSunstar Americas, Inc.\n\n301 E. Central Rd.\n\nSchaumburg, IL 60195\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\n\nUnited States\n\nWarning Letter # 614058\n\nDecember 21, 2021\n\nDear Mr. McMahon:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug and medical device manufacturing facility, Sunstar Americas, Inc., FEI 1413787, at 301 E. Central Rd., Schaumburg, Illinois, from January 12 to February 18, 2021.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals and Quality System (QS) regulations for medical devices. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211) and Title 21 CFR, part 820, respectively.\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nUnder section 201(h) of the FD&C Act, 21 U.S.C. § 321(h), G•U•M® HYDRAL™ OTC products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. The HYDRAL™ OTC products are intended for treatment of Xerostomia\u002Fdry mouth.\n\nThis inspection also revealed that your devices are adulterated within the meaning of section 501(h) of the FD&C Act, 21 U.S.C. § 351(h) because the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation.\n\nWe reviewed your March 11, 2021, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nDrug CGMP Violations\n\n1. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of its written production and process control procedures (21 CFR 211.100(a) and (b)).\n\nOur investigators documented deficiencies in the “(b)(4) system) validation protocol and deviations during its execution. For example:\n\n• Excursions in the performance parameters of your water system occurred while the system was being validated. For example, the (b)(4) concentration, which impacts the ability of the system to maintain microbiological control, was recorded at (b)(4) in the system storage tank. (b)(4) measurements were below the limit of (b)(4) for (b)(4) out of (b)(4) days in January 2018. These occurrences were not documented in the validation report as deviations and reviewed before you deemed the water system validated.\n\n• The water system validation study did not provide scientific data supporting the type and frequency of chemical sanitization performed in addition to the routine (b)(4) sanitization. Your protocol also lacked provisions for evaluating these parameters of your water system sanitization program. Your current practice is to conduct chemical sanitization (b)(4).\n\n• The protocol allowed for reduced sampling and testing if results were considered acceptable but you did not define what an acceptable standard would be. Although you had results as high as (b)(4) at your (b)(4), you still reduced sampling and testing to a (b)(4) frequency.\n\nYou have not shown that your water system can consistently produce water suitable for drug manufacturing and meets, at a minimum, the USP purified water monograph and appropriate microbial limits.\n\nIt is essential that you design your water system to ensure consistently high purity water that is suitable for its intended use. High bioburden or objectionable microbes in the water used as an ingredient in your drugs may pose significant risk to consumers.\n\nIn your response, you committed to reassessing your water system followed by revalidation. You also committed to conducting a gap assessment of your validation program and performing comprehensive CGMP and quality systems training for all personnel.\n\nIn response to this letter provide:\n\n• A comprehensive independent assessment of your water system design, control, and maintenance, and corresponding corrective actions and preventative actions (CAPA).\n\n• A thorough remediation plan to install and operate a suitable water system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system design or new system consistently produces water adhering to (b)(4) Water, USP monograph specifications and appropriate microbial limits (total counts, objectionable microbes).\n\n• Regarding the latter, ensure that your total microbial count limit for water is appropriate in view of the intended use of the products produced by your firm.\n\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour water system was subject to microbiological contamination and numerous deviations from operating parameters since validation. Many of these deviations were either not investigated or did not result in implementation of CAPA.\n\n• No investigations were conducted in response to identification of Burkholderia contaminans in seven samples taken from your water system ports (b)(4), and (b)(4), between January 1, 2020, and June 30, 2020. Burkholderia contaminans was not identified as an objectionable organism in your procedures or your (b)(4) water specifications. The presence of objectionable microorganisms in your (b)(4) water system can adversely affect the quality of your drug products.\n\n• You opened a CAPA during the validation of your water system due to findings of Burkholderia cepacia in three samples collected at ports (b)(4) and (b)(4). These ports supply water for manufacturing. The CAPA investigation identified a possible root cause of a “(b)(4)” from the (b)(4) supply port to the (b)(4) sample port and your firm proposed (b)(4). However, the CAPA was closed approximately a year and a half later without addition of the filter or explanation why corrective action was not taken. You subsequently identified Burkholderia contaminans at port (b)(4) multiple times in 2020.\n\n• During the validation of your water system, a third-party service technician observed staining inside the water tank and noted you were investigating the cause. You lacked documentation of the cause or CAPA addressing the service technician’s finding.\n\n• Deviations in the (b)(4) sanitization process were not logged in accordance with your deviation procedure. We found a pattern of failure to conduct investigations or implement CAPA following deviations in the operating parameters during ozone sanitization when the minimum level of (b)(4) was not met in the storage tank, (b)(4), and loop supply.\n\nIn your response, you committed to hire a third-party expert and to perform training on investigations. You also committed to performing a review of all CAPA, out-of-specification (OOS), out-of-trend (OOT), and invalidated quality control data initiated from January 1, 2019, to present. You also revised your purified water specifications to include Burkholderia cepacia complex (BCC) as an objectionable organism as of January 11, 2021.\n\nYour response is inadequate because you failed to accurately categorize some OOS and OOT results, deviations, and unexpected discrepancies.\n\nIn response to this letter, provide:\n\n• A retrospective, independent review of all invalidated OOS (including in-process, release, and stability testing) results for US products irrespective of whether the batch was ultimately distributed in the US and a report summarizing the findings of the analysis, including the following for each OOS:\n\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\n\no For investigations that conclusively establish laboratory root cause, provide the rationale, and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\n\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\n\n• A comprehensive retrospective review of all GMP documentation associated with distributed finished drug product batches that remain within expiry and the equipment and systems used in their manufacture to ensure all OOS results, OOT results, deviations, and unexpected discrepancies were categorized and appropriately investigated.\n\n• Explain whether you have reconsidered the sequence of the water system components in your current design. You currently have (b)(4) system although the latter represents the best means of microbial reduction.\n\n• A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\n• A detailed description of all CAPA that have been identified to address this violation, with timeframes for CAPA activities.\n\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\nBefore beginning distribution, you did not adequately study antimicrobial effectiveness in your finished drugs products to evaluate the ability of the preservative system to inhibit the growth of certain objectionable organisms including BCC.\n\nFor example, (b)(4) studies for 0.12% chlorhexidine gluconate oral rinse (Paroex) using Burkholderia cepacia were not performed until July 2020. Notably, BCC was found to proliferate to excessive levels in your product over its shelf life for several batches including too numerous to count (TNTC) levels. Numerous lots of this product were recalled from the market because of excessive microbiological contamination. Paroex is produced by a contract manufacturer under your ANDA 076434.\n\nIn your response, you committed to assessing your procedure titled “U.S. Regulatory Information Concerning SAI Products” to determine its adequacy in establishing and maintaining product-specific information and meeting regulatory requirements.\n\nYou committed to adding BCC to microbiological tests for products manufactured at and for your firm. You also committed to developing and implementing a procedure to establish steps to follow when a new microorganism is identified in the manufacturing facility to ensure the adequacy of controls, including addressing potentially objectionable microorganisms.\n\nIn response to this letter, describe how your product and process development programs will build quality into your products, including conducting appropriate studies to support each new product.\n\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nYou did not adequately exercise your responsibility to ensure all drug products manufactured by and for your firm possessed appropriate quality attributes, antimicrobial properties, or preservative systems to ensure their microbiological quality and safety. For example, your non-sterile aqueous-based drug product specifications did not include Burkholderia cepacia.\n\nYour drugs are often used in hospitals or clinical settings in which patients may have a higher vulnerability to infection with Burkholderia cepacia and other objectionable organisms. Detecting numbers and types of objectionable microorganisms in your drug products is critical to making appropriate batch disposition decisions.\n\nThe agreement between your firm and your contract manufacturer ((b)(4)) specifically identified your responsibilities with respect to the manufacture of your drug products. Your responsibilities include the provision of support regarding technical and regulatory issues to (b)(4) for the products’ manufacture. You are also responsible for overseeing the CGMP compliance of your contract manufacturer through mechanisms including the review of procedures and records associated with the manufacture of your products.\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nWe acknowledge that you initially recalled batches of Paroex bearing an expiration date from June 30, 2022, to September 30, 2022, because of the presence of objectionable microbiological contamination or substantial risk of contamination. We also acknowledge your expansion of the recall to include all potentially affected lots of Paroex following further discussions with FDA. We also acknowledge your subsequent recalls of Hydral Dry Mouth Relief, Butler Clear Dip, and Perioshield Oral Health Rinse, medical devices, because of potential contamination with objectionable organisms.\n\nYou are responsible for the quality of your drugs regardless of whether you manufacture them, or a contract facility manufactures them for you on your behalf. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity.\n\nIn response to this letter, provide your updated procedures that ensure all activities performed by you and your contract manufacturers are adequate and approved by your quality unit.\n\nMedical Device Quality System Violations\n\n5. Your firm failed to adequately validate a process whose results cannot be fully verified by subsequent inspection and test through established procedures (21 CFR 820.75(a)).\n\nRefer above to the discussion of 21 CFR 211.100(a) and (b) violations.\n\n6. Your failed to adequately establish procedures for corrective and preventive action to include the documentation of such activities (21 CFR 820.100(a) & (b)).\n\nRefer above to the discussion of 21 CFR 211.192 violations.\n\n7. Failure to adequately establish schedules for the adjustment, cleaning, and other maintenance of equipment (21 CFR 820.70(g)).\n\nSpecifically, the (b)(4) Sanitization system of the (b)(4) water system was not part of a maintenance schedule. The system included three gauges that measure the (b)(4) in the system to verify that the sanitization process and the storage tank control are acceptable. There was no documentation that gauges ((b)(4)) had been calibrated.\n\n8. Failure to adequately establish procedures for design input (21 CFR 820.30(c)).\n\nSpecifically, the design for Hydral Spray failed to include Burkholderia cepacia as a challenge in (b)(4) although Burkholderia cepacia was included in the (b)(4) challenge for other products to include the (b)(4) toothpaste in June 2017. The risk management file of the Hydral Spray was not updated to include these objectionable organisms and any controls necessary to mitigate the risks as part of Hydral spray design verification and validation. The risk management file was updated on January 18, 2021, after the start of the FDA inspection.\n\nQuality Systems\n\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q8(R2) Pharmaceutical Development at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71535\u002Fdownload, Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71543\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nObjectionable Organisms\n\nFor further information regarding the significance of Burkholderia cepacia complex and other objectionable contamination of non-sterile, water-based drug products, see FDA’s advisory notice posted on July 7, 2021, at https:\u002F\u002Fwww.fda.gov\u002FDrugs\u002FDrugSafety\u002Fucm559508.htm.\n\nDrug Production Suspended\n\nWe acknowledge your commitment to suspend production of drugs at this facility.\n\nIf you plan to resume manufacturing drugs, notify this office before resuming your operations.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility and in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done since our inspection to correct your violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to the Warning Letter Number above (614058). Please address your reply via email to: oradevices2firmresponse@fda.hhs.gov\n\nAttention: Rafael Padilla. Compliance Officer\n\nU.S. Food and Drug Administration\n\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\n\nIf you have questions regarding the contents of this letter, please contact Rafael Padilla at (312) 596-4212.\n\nSincerely,\n\n\u002FS\u002F\n\nBlake Bevill, M.S.\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological Health Operations Div. 2 Central\n\nSincerely,\n\n\u002FS\u002F\n\nJeffrey Meng\n\nActing Program Division Director\n\nDivision of Pharmaceutical Quality Operations Division III","Sunstar Americas, Inc.","sunstar-americas-inc-614058-12212021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsunstar-americas-inc-614058-12212021","2026-10-26T08:10:07.599719+00:00","2022-01-18","614058","Medical Devices","Mr. Richard McMahon","2026-08-20T02:16:16.278+00:00","UPS","2021-12-21",{"id":55,"raw":56,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":19,"letter_url":67,"updated_at":68,"action_type":22,"case_status":23,"posted_date":69,"marcs_cms_no":70,"product_type":71,"closeout_date":19,"issuing_office":60,"recipient_name":72,"body_fetched_at":73,"delivery_method":74,"recipient_title":19,"reference_number":75,"action_taken_date":76,"medical_device_id":19,"response_letter_date":19},139,[57,58,59,60,61,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-14T04:00:00Z\">05\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026\">GC America, Inc.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-76\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Joseph T. Talanges\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President &amp; Chief Operating Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>GC America, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3737 West 127th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alsip\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60803\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 14, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Talanges:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures OTC drug products, including those for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm failed to ensure components were suitable for use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> \u003Cem>Used as a Component in Drug Products\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not adequately demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, at a minimum, meets specifications in the United States Pharmacopeia (USP) \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system records show that you only performed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing \u003Cstrong>(b)(4) \u003C\u002Fstrong>sampling requirements and acceptance criteria. According to your management, you manufactured approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> finished drug batches with inadequately tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> from 2023 through 2025.\u003C\u002Fp>\u003Cp>\u003Cem>Products Containing Ingredients at Risk for \u003C\u002Fem>\u003Cstrong>(b)(4) \u003C\u002Fstrong>\u003Cem>Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination before using them to manufacture your drug products. This includes, but is not limited to, testing \u003Cstrong>(b)(4)\u003C\u002Fstrong> to determine its appropriate identity prior to use in manufacturing your drug products.\u003C\u002Fp>\u003Cp>Identity testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for \u003Cstrong>(b)(4)\u003C\u002Fstrong> levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not perform all testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> per USP, and you commit to sending a sample of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on drug products released from 2023 to 2025 and to establishing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing SOP.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a detailed procedure explaining how you will assess your \u003Cstrong>(b)(4)\u003C\u002Fstrong> against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\u003C\u002Fp>\u003Cp>Without adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fp>\u003Cp>• The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fp>\u003Cp>• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> USP monograph specifications and appropriate microbial limits.\u003C\u002Fp>\u003Cp>• A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003C\u002Fp>\u003Cp>• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\u003C\u002Fp>\u003Cp>• Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system qualification report.\u003C\u002Fp>\u003Cp>• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\u003C\u002Fp>\u003Cp>• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the USP monograph.\u003C\u002Fp>\u003Cp>• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fp>\u003Cp>• A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\u003Cbr>• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for \u003Cstrong>(b)(4)\u003C\u002Fstrong> consisted of a single batch tested for \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\u003C\u002Fp>\u003Cp>Without an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Q1A(R2) Stability Testing of New Drug Substances and Products\u003C\u002Fem> to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\u003C\u002Fp>\u003Cp>Your response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>o detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>o all procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter affixed to a laptop by a sticker used for processing \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter test results. In addition, the data from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\u003C\u002Fp>\u003Cp>Your QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\u003C\u002Fp>\u003Cp>In your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fp>\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003Cbr>\u003Cbr>• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fp>\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\u003Cp>• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003Cbr>\u003Cbr>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>Kennerly K. Chapman -S\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Digitally signed by Kennerly K. Chapman -S\u003Cbr>Date: 2026.05.14 15:58:58 -04'00'\u003Cbr>Office of Manufacturing Quality Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-76\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Joseph T. Talanges\n\nRecipient Title\n\nPresident & Chief Operating Officer\n\nGC America, Inc.\n\n3737 West 127th Street\n\nAlsip, IL 60803\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 14, 2026\nWARNING LETTER\n\nDear Mr. Talanges:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, GC America, Inc., FEI 1410097, at 3737 West 127th Street, Alsip, Illinois, from November 3 to 7, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your November 21, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYour firm manufactures OTC drug products, including those for (b)(4). Your firm failed to ensure components were suitable for use in manufacturing your drug products.\n(b)(4) Used as a Component in Drug Products\nYou did not adequately demonstrate your (b)(4), at a minimum, meets specifications in the United States Pharmacopeia (USP) (b)(4) monograph. For example, your (b)(4) system records show that you only performed (b)(4) testing. However, the USP monograph requires additional testing for chemical purity and microbial quality. We also noted you failed to establish a procedure describing (b)(4) sampling requirements and acceptance criteria. According to your management, you manufactured approximately (b)(4) finished drug batches with inadequately tested (b)(4) from 2023 through 2025.\nProducts Containing Ingredients at Risk for (b)(4) Contamination\nYou also state in your correspondence to the agency that you do not conduct identity testing on each shipment of each lot of your incoming components at high risk of (b)(4) contamination before using them to manufacture your drug products. This includes, but is not limited to, testing (b)(4) to determine its appropriate identity prior to use in manufacturing your drug products.\nIdentity testing for (b)(4) and certain other high-risk drug components includes a USP limit test to ensure the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4).\nIn your response, you acknowledge you do not perform all testing of (b)(4) per USP, and you commit to sending a sample of your (b)(4) to a third-party testing laboratory. You also commit to conducting a risk assessment of your deficient (b)(4) testing on drug products released from 2023 to 2025 and to establishing a (b)(4) testing SOP.\nYour response is inadequate. You do not provide a detailed procedure explaining how you will assess your (b)(4) against compendial requirements. You also lack a comprehensive review of your material system, including supplier evaluations, to ensure the quality of all materials is consistently acceptable.\nWithout adequate testing, you do not have scientific evidence that components conform to appropriate specifications prior to use in the manufacture of your drug products. As a manufacturer, you have a responsibility to adequately sample, test, and examine drug components before use in production to assure quality.\nIn response to this letter, provide:\n• A procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\n• The current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) system. Ensure that the total count limits for your (b)(4) are appropriately stringent in view of the intended use of each of the products produced by your firm.\n• A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4) USP monograph specifications and appropriate microbial limits.\n• A comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\n• Based on a thorough review, provide a summary of your systems corrective actions and preventive actions (CAPA) to remediate the vendor qualification program and prevent use of unsuitable components, containers and closures.\n• Your (b)(4) system qualification report.\n• The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing, including high risk drug components.\n• A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificates of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of (b)(4) of the USP monograph.\n• A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n• A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\n• A full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPA that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n2. Your firm failed to establish and follow a written testing program designed to assess the stability characteristics of drug products and to test an adequate number of batches of each drug product to determine appropriate storage conditions and expiration dates (21 CFR 211.166(a) and 211.166(b)).\nYour firm failed to establish a stability program with adequate data from long-term or accelerated storage conditions, demonstrating that drug products remain acceptable throughout the labeled expiry period. For example, the only stability data provided for (b)(4) consisted of a single batch tested for (b)(4) at (b)(4) degrees Celsius with no controlled humidity condition. Furthermore, you have no ongoing stability studies for any drugs currently manufactured.\nWithout an appropriate stability program, you lack adequate scientific evidence to demonstrate your drug products meet established specifications and retain their quality attributes through your labeled expiry.\nSee FDA’s guidance document Q1A(R2) Stability Testing of New Drug Substances and Products to help you meet the CGMP requirements for stability testing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71707\u002Fdownload.\nIn your response, you acknowledge you do not have an appropriate written testing program to assess the stability characteristics of your drugs. You also state you will test expired reserve samples and perform a risk assessment for distributing drugs without adequate stability data. You also commit to initiating ongoing stability testing and modifying your procedures to include updated stability instructions.\nYour response is inadequate. You lack analytical data to show your drugs maintain their quality attributes throughout their shelf life. You also fail to provide updated procedures and training records indicating you have implemented an adequate stability program.\nIn response to this letter, provide:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no an ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\no detailed definition of the specific attributes to be tested at each station (timepoint)\no all procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit (21 CFR 211.22(d)).\nYour quality unit (QU) did not adequately oversee your drug manufacturing operations. For example, your QU failed to ensure adequate control of your analytical data. Our investigator documented an uncontrolled password for the (b)(4) meter affixed to a laptop by a sticker used for processing (b)(4) meter test results. In addition, the data from the (b)(4) meter is automatically deleted when the laptop is shutdown, so no records were available to show that your QU reviewed this data. Furthermore, you were unable to provide audit trails or an SOP describing oversight and retention requirements of electronic records. The lack of proper electronic record controls undermines the reliability and integrity of your laboratory data (21 CFR 211.68(b)).\nYour QU also failed to perform annual product reviews of your drug products since our previous inspection in 2018. Furthermore, no written procedures for this requirement were available (21 CFR 211.180(e)).\nIn your response, you acknowledge you did not exercise appropriate controls to ensure authorized access to electronic records. Also, you commit to removing shared passwords, creating a data integrity policy, and implementing an annual product review procedure.\nYour response is inadequate. You do not provide updated procedures and training records to demonstrate you have corrected your data control deficiencies. You also lack product quality assessments.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain a qualified consultant to assist in your remediation. In response to this letter, provide:\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting including results of the data review for drugs distributed in the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global corrective action and preventive action plan. The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n• A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a qualified consultant as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of export certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1410097 and ATTN: Matthew Jensen.\n\nSincerely,\nKennerly K. Chapman -S\nFrancis Godwin\nDirector\nDigitally signed by Kennerly K. Chapman -S\nDate: 2026.05.14 15:58:58 -04'00'\nOffice of Manufacturing Quality Office of Compliance\nCenter for Drug Evaluation and Research","GC America, Inc.","gc-america-inc-727602-05142026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgc-america-inc-727602-05142026","2026-10-26T08:08:44.827832+00:00","2026-05-26","727602","Drugs Over-the-Counter Drugs","Mr. Joseph T. Talanges","2026-08-19T04:39:48.869+00:00","Via Email Return Receipt Requested","320-26-76","2026-05-14",{"id":78,"raw":79,"subject":84,"body_html":85,"body_text":86,"firm_name":87,"letter_id":88,"created_at":66,"fei_number":19,"letter_url":89,"updated_at":90,"action_type":22,"case_status":23,"posted_date":91,"marcs_cms_no":92,"product_type":26,"closeout_date":19,"issuing_office":83,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},292,[80,81,82,83,84,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-24T04:00:00Z\">09\u002F24\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-americas-supermercado2-inc-716877-09242025\">Las Americas Supermercado#2 Inc. \u003C\u002Fa>","Division of Southwest Imports","Foreign Supplier Verification Program (FSVP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Antonio Perez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Las Americas Supermercado#2 Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2415 E Admiral Pl\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tulsa\u003C\u002Fspan>, \u003Cspan>OK\u003C\u002Fspan> \u003Cspan>74110-5343\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Southwest Imports\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>09\u002F24\u002F2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 716877\u003C\u002Fp>\u003Cp>Dear Mr. Antonio Perez:\u003C\u002Fp>\u003Cp>From 08\u002F28\u002F2025 to 09\u002F08\u002F2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Las Americas Supermercado#2 Inc. located at 2415 E Admiral Pl, Tulsa, OK 74110-5343. We also conducted an inspection from 06\u002F09\u002F2021 to 06\u002F23\u002F2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>The FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\u003C\u002Fp>\u003Cp>During the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\u003C\u002Fp>\u003Cp>We acknowledge receipt of your response, dated 09\u002F09\u002F2025, in which you stated you were unaware your firm was inspected in 2021 and described your intention to take corrective actions. Additionally, you stated, \u003Cstrong>(b)(6)\u003C\u002Fstrong> started training on the Foreign Supplier Verification Program (FSVP) regulations.\u003C\u002Fp>\u003Cp>We are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\u003C\u002Fp>\u003Cp>Your significant violations of the FSVP regulation are as follows:\u003C\u002Fp>\u003Cp>You did not develop, maintain, and follow an FSVP as required by section 805 of the FD&amp;C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\u003C\u002Fp>\u003Cp>Cabbage, imported from, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>Green Prickly Pear, imported from, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>Fresh Cilantro, imported from, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, located in \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&amp;C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112)]\u003C\u002Fp>\u003Cp>The above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&amp;C Act and the implementing regulation in 21 CFR part 1, subpart L.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&amp;C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&amp;C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&amp;C Act (21 U.S.C. 331(zz)).\u003C\u002Fp>\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\u003C\u002Fp>\u003Cp>Please send your reply to Food and Drug Administration, Attention: Santiago Gallardo Johnson, Compliance Officer, the Division of Southwest Imports, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Santiago Gallardo Johnson via email at santiago.gallardojohnson@fda.hhs.gov. Please reference CMS # 716877 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Todd Cato\u003Cbr>Program Division Director\u003Cbr>Division of Southwest Imports\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAntonio Perez\n\nRecipient Title\n\nOwner\n\nLas Americas Supermercado#2 Inc.\n\n2415 E Admiral Pl\n\nTulsa, OK 74110-5343\n\nUnited States\n\n(b)(6)\n\nIssuing Office:\n\nDivision of Southwest Imports\n\nUnited States\n\n09\u002F24\u002F2025\nWARNING LETTER\nRe: CMS # 716877\nDear Mr. Antonio Perez:\nFrom 08\u002F28\u002F2025 to 09\u002F08\u002F2025, the Food and Drug Administration (FDA) conducted a Foreign Supplier Verification Program (FSVP) inspection of Las Americas Supermercado#2 Inc. located at 2415 E Admiral Pl, Tulsa, OK 74110-5343. We also conducted an inspection from 06\u002F09\u002F2021 to 06\u002F23\u002F2021. These inspections were conducted to determine compliance with the requirements of section 805 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 384a) and the implementing FSVP regulation in 21 CFR part 1, subpart L.\nThe FSVP regulation requires that importers perform certain risk-based activities to verify that human and\u002For animal food they import into the United States has been produced in a manner that meets applicable U.S. food safety standards. You may find information relating to the FSVP regulation and your responsibilities to comply with the regulation through links in FDA’s FSVP web page at https:\u002F\u002Fwww.fda.gov\u002Ffood\u002Ffood-safety-modernization-act-fsma\u002Ffsma-final-rule-foreign-supplier-verification-programs-fsvp-importers-food-humans-and-animals.\nDuring the most recent inspection, we found that you are not in compliance with the requirements of 21 CFR part 1, subpart L for the foods you import. Because of these significant violations, you are not in compliance with section 805 of the FD&C Act.\nAt the conclusion of the inspection, our investigator provided you with a Form FDA 483a FSVP Observations.\nWe acknowledge receipt of your response, dated 09\u002F09\u002F2025, in which you stated you were unaware your firm was inspected in 2021 and described your intention to take corrective actions. Additionally, you stated, (b)(6) started training on the Foreign Supplier Verification Program (FSVP) regulations.\nWe are unable to evaluate the adequacy of your response because you have not provided any supporting documentation demonstrating your corrective actions. To date, no additional FSVP documents have been received by FDA.\nYour significant violations of the FSVP regulation are as follows:\nYou did not develop, maintain, and follow an FSVP as required by section 805 of the FD&C Act and 21 CFR 1.502(a). Specifically, you did not develop an FSVP for any of the foods you import, including each of the following foods:\nCabbage, imported from, (b)(4), located in (b)(4)\nGreen Prickly Pear, imported from, (b)(4), located in (b)(4)\nFresh Cilantro, imported from, (b)(4), located in (b)(4)\nYou import fresh produce that may be considered “covered produce” as defined in 21 CFR 112.3. If after review of the fresh produce that you import you determine that you are an importer of covered produce, you must have an FSVP that demonstrates that your supplier is producing the food in compliance with processes and procedures that provide at least the same level of public health protection as those required under section 419 of the FD&C Act (21 U.S.C. 350h) (regarding standards for produce safety) and the implementing regulations in the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption (21 CFR part 112)]\nThe above violations are not intended to be an all-inclusive list of violations of the FSVP requirements. It is your responsibility to ensure that you are in compliance with section 805 of the FD&C Act and the implementing regulation in 21 CFR part 1, subpart L.\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you do not adequately address this matter, we may take further action. For instance, we may take action under section 801(a)(3) of the FD&C Act (21 U.S.C. 381(a)(3)) to refuse admission of the food you import for which you appear to be in violation of section 805. We may place the foods you import into the United States on detention without physical examination (DWPE) when you import the foods. You can find DWPE information relating to FSVP in Import Alert # 99-41 at http:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html. In addition, the importation or offering for importation into the United States of an article of food without the importer having an FSVP that meets the requirements of section 805 of the FD&C Act or the FSVP regulation is prohibited under section 301(zz) of the FD&C Act (21 U.S.C. 331(zz)).\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should address the specific things you are doing to correct any violations. You should include in your response documentation and information that would assist us in evaluating your corrections (e.g., documentation of changes you made, such as a copy of your FSVP, records to demonstrate implementation of your FSVP), and any additional information that you wish to supply relevant to your compliance with the FSVP regulation. If you believe that you are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within 15 working days, you should explain the reason for your delay and state when you will correct any remaining violations.\nPlease send your reply to Food and Drug Administration, Attention: Santiago Gallardo Johnson, Compliance Officer, the Division of Southwest Imports, 9777 Via de la Amistad, Suite 131, San Diego, CA 92154. If you have any questions regarding this letter, or wish to send your response electronically, you may contact Santiago Gallardo Johnson via email at santiago.gallardojohnson@fda.hhs.gov. Please reference CMS # 716877 on any documents or records you provide to us and on the subject line of any email correspondence you send to us.\nSincerely,\n\u002FS\u002F\nTodd Cato\nProgram Division Director\nDivision of Southwest Imports","Las Americas Supermercado#2 Inc.","las-americas-supermercado2-inc-716877-09242025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-americas-supermercado2-inc-716877-09242025","2026-10-26T08:09:12.457441+00:00","2026-03-03","716877","Antonio Perez","2026-08-19T04:54:51.853+00:00","Via Express Delivery","2025-09-24",4,{"510k":99,"classification":100,"enforcement":101,"event":102,"event_backfill":103,"pma":104,"warning_letter":105},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]